An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)

Gossamer Bio USA, Inc.

Summary

This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

Description

The treatment period is planned to run until the market approval of seralutinib or until the study is terminated.

Eligibility

Age range: 18–75 years
Sex: All
Healthy volunteers: No

Detailed criteria

An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)

Summary

Description

Eligibility

Interventions

Locations (120)